Supplementary Table 8.
Change in Enterobacteriaceae Relative Abundance From Baseline to 8 Weeks Post Treatment Across Arms
| Arms | No. of subjects | Median Enterobacteriaceae log2FC | P value |
|---|---|---|---|
| Placebo/placebo | 4 | 2.758 | .875 |
| Placebo/SER-287 weekly | 8 | 0.229 | .945 |
| Vancomycin/SER-287 weekly | 10 | –3.061 | .064 |
| Vancomycin/SER-287 daily | 7 | –1.183 | .156 |
| Vancomycin/SER-287 weekly + daily | 17 | –1.377 | .009 |
NOTE. The change in Enterobacteriaceae abundance was assessed at 8 weeks post treatment. Only subjects with baseline and 8-week stool samples and subjects with Enterobacteriaceae at baseline (n = 29) were included in analyses. Change in Enterobacteriaceae abundance post treatment was assessed using log2 fold-change between subjects' baseline and 8-week post-treatment samples. A 2-sided Wilcoxon signed-rank test was performed to assess whether the fold-changes were centered around 0 for each arm individually and for vancomycin/SER-287 weekly and daily treatment arms combined.